EICHORCondition: Non-Small Cell Lung Cancer · Colorectal Cancer · Breast Cancer · Sponsor: Fate Therapeutics
This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.
This description comes directly from the study's public registry record.
Fate Trial Disclosure · 858-875-1800 · FateTrialDisclosure@fatetherapeutics.com
Always discuss trial participation with your own doctor first.
| University of Southern California | La Jolla, California, United States | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| University of Minnesota Masonic Cancer Center | Minneapolis, Minnesota, United States | Recruiting |
| Thomas Jefferson University, Sidney Kimmel Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| M. D. Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07216105